BIO-RAD LABORATORIES-A (BIO)
US0905722072 - Common Stock
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Thursday Sector Laggards: Technology & Communications, Healthcare
What's going on in today's session: S&P500 gap up and gap down stocks
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Discover the top S&P500 movers in Thursday's pre-market session and stay informed about market dynamics.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Commit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using Options
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
Which S&P500 stocks are moving on Tuesday?
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Notable Two Hundred Day Moving Average Cross - BIO
Monday Sector Laggards: Industrial, Healthcare
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
AGCO Larger Than S&P 500 Component Bio-Rad Laboratories
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
Friday Sector Leaders: Materials, Healthcare
Noteworthy Friday Option Activity: MCD, BIO, DLTR
Bullish Two Hundred Day Moving Average Cross - BIO
S&P 500 Movers: DLR, AMAT
Bio-Rad Labs Non-GAAP EPS of $3.10 beats by $0.23, revenue of $681.2M misses by $5.4M (NYSE:BIO)
Bio-Rad Labs reports Q4 Non-GAAP EPS beat of $3.10 by $0.23, but revenue misses by $5.4M.
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
Friday Sector Leaders: Consumer Products, Healthcare
Danaher stock rises as Sartorius beats in Q4 (NYSE:DHR)
U.S. life sciences toolmakers Danaher (DHR), Repligen (REGN), and Bio-Rad (BIO) see gains as German peer Sartorius (SARTF) posts strong Q4 2023 results. Read more here.
S&P 500 Movers: INTC, BIO
Acadia Healthcare Company Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Gentex Larger Than S&P 500 Component Bio-Rad Laboratories
Agree To Purchase Bio-Rad Laboratories At $290, Earn 12% Annualized Using Options
BILL Holdings Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories
Murphy USA Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories
Graphic Packaging Holding Larger Than S&P 500 Component Bio-Rad Laboratories
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
Donaldson Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories
Royal Gold Larger Than S&P 500 Component Bio-Rad Laboratories